Mirion Lifts Sales Outlook, Cuts Top Of EBITDA Range To $292 Million From $300 Million
Third-quarter revenue rose 24.5% to $277.8 million, and the company raised its cash flow outlook as it narrowed profit ranges.
Mirion Technologies, which makes radiation detection and monitoring products, raised its 2026 revenue growth outlook to about 24%-25% from 22%-24% but lowered the top of its adjusted EBITDA range to $292 million from $300 million, according to its third-quarter results on Tuesday. Third-quarter revenue rose 24.5% to $277.8 million from $223.1 million a year earlier.
Orders jump, margins slip
Net income was $7.8 million, or $0.03 a share, against $3.1 million, or $0.01, a year earlier. Adjusted earnings per share was flat at $0.12, and adjusted EBITDA (earnings before interest, taxes, depreciation and amortization, with adjustments) rose to $64.8 million from $52.4 million. The adjusted EBITDA margin slipped to 23.3% from 23.5%.
Orders excluding the Paragon and Certrec acquisitions were $340 million, up 62% from $209 million. Including them, orders were $386 million, up 85%.
Chairman and CEO Thomas Logan said orders were "boosted by a 105% increase in nuclear power-related orders." Organic revenue, which strips out currency and acquisitions, rose 6.5%.
Guidance moves in both directions
The company revised several 2026 targets:
- Organic revenue growth of about 7%-8%, from 5%-7%.
- Adjusted EBITDA of about $285 million-$292 million, from $285 million-$300 million.
- Adjusted free cash flow of about $170 million-$185 million, from $155 million-$175 million.
- Adjusted EPS of about $0.50-$0.54, from $0.48-$0.55.
Logan said the company was updating guidance "to reflect increased visibility to full year performance." He said he expects mid-to-high teens organic growth in the fourth quarter.
Cash flow and the nuclear fleet
Adjusted free cash flow was $47 million in the quarter and $107 million for the first nine months, which Logan described as a doubling. He said net leverage should fall to about 2.6x by year-end.
Mirion sells to nuclear power plants, labs and defense customers, and its Medical segment sells cancer care quality assurance tools and dosimetry services. Logan said the company has a presence in over 98% of commercial nuclear plants globally, and that approximately 80% of its nuclear power-related revenue comes from reactors operating today.
Mirion hosts a conference call on Wednesday at 10:00 a.m. ET to discuss the results and the revised 2026 forecast.